You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,855,338


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,855,338
Title: Anti-tumor therapies comprising a combination of a cartilage extract and an anti-neoplastic agent providing high efficacy and low toxic side effects
Abstract:This invention described a novel use for cartilage extract, namely a shark cartilage extract, in a combined anti-tumor therapy. The cartilage extract is used in combination with anti-neoplastics. The combined therapy provides for a higher anti-tumor efficacy with no concomitant increase, even better with a decrease, of toxic side effects.
Inventor(s): Dupont; Eric (Saint-Nicolas, CA)
Assignee: Les Laboratoires Aeterna, Inc. (Quebec, CA)
Application Number:10/087,041
Patent Claims:1. An anti-tumor composition comprising an anti-tumor amount of anti-neoplastic agent; a side effect-reducing amount of a shark cartilage extract; and a pharmaceutically acceptable carrier.

2. The anti-tumor composition of claim 1, wherein the anti-neoplastic agent is selected from the group consisting of busulfan, thiotepa, chlorambucil, cyclophosphamide, estramustine sodium phosphate, ifosfamide, mechlorethamine hydrochloride, melphalan, carmustine, lomustine, streptozocin, carboplatin, cisplatin, methotrexate sodium, cladribine, mercaptopurine, thioguanine, cytarabine, fluorouracil, hydroxyurea, daunorubicin, doxorubicin hydrochloride, epirubicin hydrochloride, idarubicin hydrochloride, dactinomycin, bleomycin sulfate, mitomycin, mitotane, mitoxantrone hydrochloride, etoposide, teniposide, docetaxel, paclitaxel, vinblastine sulfate, vincristine sulfate, vindesine sulfate, vinorelbine tartrate, altretamine, amsacrine, 1-asparaginase, dacarbazine, fludarabine phosphate, porfimer sodium, procarbazine hydrochloride, tretinoin (all-trans retinoic acid), marimastat, suramin, TNP 470, thalidomide and radiotherapeutics.

3. The anti-tumor composition of claim 1, wherein the anti-neoplastic agent is cisplatin.

4. The anti-tumor composition of claim 1, wherein the shark cartilage extract comprises water-soluble molecules and a major portion of the water-soluble molecules have a molecular weight of less than about 500 kDa.

5. The anti-tumor composition of claim 4, wherein the shark cartilage extract has been prepared by fractionating a crude shark cartilage extract comprising water-soluble molecules obtained from shark cartilage material such that a major portion of the molecules having a molecular weight of greater than about 500 kDa is separated from a major portion of the molecules having a molecular weight of less than about 500 kDa.

6. The anti-tumor composition of claim 1, further comprising hypoxanthine.

7. An anti-tumor composition comprising a sub-optimal dosage amount of an anti-neoplastic agent; a side effect-reducing amount of a shark cartilage extract; and a pharmaceutically acceptable carrier that is an aqueous solution,

wherein administration of the anti-tumor composition causes less side effects than administration of a similar composition that does not contain shark cartilage extract.

8. An anti-tumor composition comprising an optimal dosage amount of an anti-neoplastic agent; a side effect-reducing amount of a shark cartilage extract; and a pharmaceutically acceptable carrier that is an aqueous solution,

wherein administration of the anti-tumor composition causes less side effects than administration of a similar composition that does not contain shark cartilage extract.

9. An anti-tumor treatment kit comprising a first composition comprising a pharmaceutical dosage of an anti-neoplastic agent; and a second composition comprising a side effect-reducing amount of a shark cartilage extract.

10. The anti-tumor treatment kit of claim 9, wherein the first composition and the second composition are each independently contained within a dosage form.

11. The anti-tumor treatment kit of claim 9, wherein the anti-neoplastic agent is selected from the group consisting of busulfan, thiotepa, chlorambucil, cyclophosphamide, estramustine sodium phosphate, ifosfamide, mechlorethamine hydrochloride, melphalan, carmustine, lomustine, streptozocin, carboplatin, cisplatin, methotrexate sodium, cladribine, mercaptopurine, thioguanine, cytarabine, fluorouracil, hydroxyurea, daunorubicin, doxorubicin hydrochloride, epirubicin hydrochloride, idarubicin hydrochloride, dactinomycin, bleomycin sulfate, mitomycin, mitotane, mitoxantrone hydrochloride, etoposide, teniposide, docetaxel, paclitaxel, vinblastine sulfate, vincristine sulfate, vindesine sulfate, vinorelbine tartrate, altretamine, amsacrine, 1-asparaginase, dacarbazine, fludarabine phosphate, porfimer sodium, procarbazine hydrochloride, tretinoin (all-trans retinoic acid), marimastat, suramin, TNP 470, thalidomide and radiotherapeutics.

12. The anti-tumor treatment kit of claim 9, wherein the anti-neoplastic agent is cisplatin.

13. The anti-tumor treatment kit of claim 9, wherein the shark cartilage extract comprises water-soluble molecules, a major portion of which have a molecular weight of less than about 500 kDa.

14. The anti-tumor treatment kit of claim 9, wherein the shark cartilage extract has been prepared by fractionating a crude shark cartilage extract comprising water soluble molecules obtained from shark cartilage material such that a major portion of the molecules having a molecular weight of greater than about 500 kDa is separated from a major portion of the molecules having a molecular weight of less than about 500 kDa.

15. The anti-tumor treatment kit of claim 9, wherein the anti-neoplastic agent is present in a sub-optimal dosage amount and at least one of the first and second compositions further comprises a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is an aqueous solution, and administration of the compositions of the anti-tumor treatment kit causes less side effects than the administration of the compositions of a similar treatment kit that does not contain a composition containing shark cartilage extract.

16. The anti-tumor treatment kit of claim 9, wherein at least one of the first and second compositions further comprises a pharmaceutically acceptable carrier, wherein said pharmaceutically acceptable carrier is an aqueous solution, the anti-neoplastic agent is present in an optimal dosage amount, and administration of the compositions of the anti-tumor treatment kit causes less side effects than the administration of the compositions of a similar treatment kit that does not contain shark cartilage extract.

17. The anti-tumor treatment kit of claim 9, wherein the anti-neoplastic agent is cisplatin.

18. The anti-tumor treatment kit of claim 9, wherein the first composition is contained within a parenteral dosage form and the second composition is contained within an oral dosage form.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.